Lupus Coagulation Inhibitor
"Lupus Coagulation Inhibitor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
| Descriptor ID |
D016682
|
| MeSH Number(s) |
D12.776.124.486.485.114.323.210.600 D12.776.124.790.651.114.323.210.600 D12.776.377.715.548.114.323.210.600 D23.113.475
|
| Concept/Terms |
Lupus Coagulation Inhibitor- Lupus Coagulation Inhibitor
- Inhibitor, Lupus Coagulation
- Coagulation Inhibitor, Lupus
- Lupus Anticoagulant
- Anticoagulant, Lupus
|
Below are MeSH descriptors whose meaning is more general than "Lupus Coagulation Inhibitor".
Below are MeSH descriptors whose meaning is more specific than "Lupus Coagulation Inhibitor".
This graph shows the total number of publications written about "Lupus Coagulation Inhibitor" by people in this website by year, and whether "Lupus Coagulation Inhibitor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Lupus Coagulation Inhibitor" by people in Profiles.
-
Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality. Arthritis Rheumatol. 2021 11; 73(11):1976-1985.
-
Coronavirus-disease-2019-induced antiphospholipid-like syndrome: a case report. J Med Case Rep. 2021 Jul 29; 15(1):408.
-
The Role of Antiphospholipid Antibodies in COVID-19. Curr Rheumatol Rep. 2021 07 14; 23(9):72.
-
Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep. 2021 07 03; 23(8):65.
-
Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Semin Thromb Hemost. 2022 Feb; 48(1):55-71.
-
Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):294-297.
-
Transient endothelial injury and release of lupus anticoagulant in COVID-19. J Thromb Thrombolysis. 2022 Jan; 53(1):228-230.
-
Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev. 2021 Jun; 20(6):102822.
-
Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19. J Stroke Cerebrovasc Dis. 2021 Jul; 30(7):105817.
-
Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson's syndrome. J Thromb Thrombolysis. 2021 Nov; 52(4):1043-1046.